In addition to pharmacogenetic markers for outcome following specific drug treatment, there are a variety of patient characteristics (e.g. lymph node metastases, age), histologic findings (e.g. neurovascular invasion, differentiation), and genetic factors (e.g. p53 expression, microsatellite instability), which appear to influence patient prognosis in colorectal cancer. This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.